Ariel Dora Stern (Ariel D Stern, Ariel Stern)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 32

Top Venues

NPJ digital medicine

Clinical pharmacology and therapeutics

The New England journal of medicine

BMJ open

Harvard Business School

Harvard University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Harvard Business School Jul 01 2019

United States

Associate Professor :: Technology and Operations Management

Harvard Business School Jul 01 2014 - Jun 30 2019

United States

Assistant Professor :: Technology and Operations Management

Education History

Harvard University

United States

PHD

Publications

Jelena Schmidt, Nienke M Schutte, Stefan Buttigieg, David Novillo Ortiz, Eric Sutherland, Michael Anderson, Bart de Witte, Michael Peolsson, Brigid Unim, Milena Pavlova, Ariel Dora Stern, Elias A Mossialos, Robin Van Kessel
Mapping the regulatory landscape for artificial intelligence in health within the European Union. NPJ digital medicine 7 (1) (2024)
Mateo Aboy, Cristina Crespo, Ariel Dora Stern
Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA's De Novo pathway. NPJ digital medicine 7 (1) (2024)
Lars Masanneck, Ariel Dora Stern
Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrails.gov. Clinical pharmacology and therapeutics (2024)
Lars Masanneck, Ariel Dora Stern
Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov. Clinical pharmacology and therapeutics 116 (1) (2024)
Caroline Marra, Ariel Dora Stern
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms. Clinical pharmacology and therapeutics 115 (5) (2024)
Caroline Marra, Ariel Dora Stern
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms. Clinical pharmacology and therapeutics 115 (5) (2024)
Jelena Schmidt, Nienke M Schutte, Stefan Buttigieg, David Novillo Ortiz, Eric Sutherland, Michael Anderson, Bart de Witte, Michael Peolsson, Brigid Unim, Milena Pavlova, Ariel Dora Stern, Elias A Mossialos, Robin Van Kessel
Mapping the regulatory landscape for artificial intelligence in health within the European Union. NPJ digital medicine 7 (1) (2024)
Michael S Sinha, Ariel Dora Stern, Arti K Rai
Four Decades of Orphan Drugs and Priorities for the Future. The New England journal of medicine 391 (2) (2024)
Lars Masanneck, Ariel Dora Stern
Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov. Clinical pharmacology and therapeutics 116 (1) (2024)
Caroline Marra, Ariel Dora Stern
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms. Clinical pharmacology and therapeutics (2024)
Mateo Aboy, Cristina Crespo, Ariel Dora Stern
Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA's De Novo pathway. NPJ digital medicine 7 (1) (2024)
Mateo Aboy, Cristina Crespo, Ariel Dora Stern
Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA's De Novo pathway. NPJ digital medicine 7 (1) (2024)
Jelena Schmidt, Nienke M Schutte, Stefan Buttigieg, David Novillo Ortiz, Eric Sutherland, Michael Anderson, Bart de Witte, Michael Peolsson, Brigid Unim, Milena Pavlova, Ariel Dora Stern, Elias A Mossialos, Robin Van Kessel
Mapping the regulatory landscape for artificial intelligence in health within the European Union. NPJ digital medicine 7 (1) (2024)
Michael S Sinha, Ariel Dora Stern, Arti K Rai
Four Decades of Orphan Drugs and Priorities for the Future. The New England journal of medicine (2024)
Lars Masanneck, Pauline Gieseler, William J Gordon, Sven G Meuth, Ariel Dora Stern
Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials. NPJ digital medicine 6 (1) (2023)
Lars Masanneck, Pauline Gieseler, William J Gordon, Sven G Meuth, Ariel Dora Stern
Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials. NPJ digital medicine 6 (1) (2023)
Mitchell Tang, Carter H Nakamoto, Ariel Dora Stern, Jose R Zubizarreta, Felippe O Marcondes, Lori Uscher-Pines, Lee S Schwamm, Ateev Mehrotra
Effects of Remote Patient Monitoring Use on Care Outcomes Among Medicare Patients With Hypertension : An Observational Study. Annals of internal medicine (2023)
Lars Masanneck, Pauline Gieseler, William J Gordon, Sven G Meuth, Ariel Dora Stern
Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials. NPJ digital medicine 6 (1) (2023)
Jan B Brönneke, Annika Herr, Simon Reif, Ariel Dora Stern
DYNAMIC HTA FOR DIGITAL HEALTH SOLUTIONS: OPPORTUNITIES AND CHALLENGES FOR PATIENT-CENTERED EVALUATION. International journal of technology assessment in health care (2023)
Mitchell Tang, Yashoda Sharma, Jennifer C Goldsack, Ariel Dora Stern
Building the Business Case for an Inclusive Approach to Digital Health Measurement With a Web App (Market Opportunity Calculator): Instrument Development Study. JMIR formative research 7 (2023)
Robin Van Kessel, Divya Srivastava, Ilias Kyriopoulos, Giovanni Monti, David Novillo Ortiz, Ran Milman, Wojciech Wilhelm Zhang-Czabanowski, Greta Nasi, Ariel Dora Stern, George Wharton, Elias A Mossialos
Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping. JMIR mHealth and uHealth 11 (2023)
Anna Essén, Ariel Dora Stern, Christoffer Bjerre Haase, Josip Car, Felix Greaves, Dragana Paparova, Steven Vandeput, Rik Wehrens, David Westfall Bates
Health app policy: international comparison of nine countries' approaches. NPJ digital medicine 5 (1) (2022)
John B Torous, Ariel Dora Stern, Florence T Bourgeois
Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 5 (1) (2022)
Keizra Mecklai, Nicholas Smith, Ariel Dora Stern, Daniel B Kramer
Remote Patient Monitoring - Overdue or Overused? The New England journal of medicine 384 (15) (2021)
Jan Benedikt Brönneke, Jennifer Müller, Konstantinos Mouratis, Julia Hagen, Ariel Dora Stern
Regulatory, Legal, and Market Aspects of Smart Wearables for Cardiac Monitoring. Sensors (Basel, Switzerland) 21 (14) (2021)
William J Gordon, Andrea R Coravos, Ariel Dora Stern
Ushering in safe, effective, secure, and ethical medicine in the digital era. NPJ digital medicine 4 (1) (2021)
Caroline Marra, William J Gordon, Ariel Dora Stern
Use of connected digital products in clinical research following the COVID-19 pandemic: a comprehensive analysis of clinical trials. BMJ open 11 (6) (2021)
Sara Gerke, Ariel Dora Stern, Timo Minssen
Germany's digital health reforms in the COVID-19 era: lessons and opportunities for other countries. NPJ digital medicine 3 (2020)
Noy Alon, Ariel Dora Stern, John B Torous
Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification With Top Health Apps in the United States: Quality Improvement Study. JMIR mHealth and uHealth 8 (10) (2020)
William J Gordon, Ariel Dora Stern
Challenges and opportunities in software-driven medical devices. Nature biomedical engineering 3 (7) (2020)
Caroline Marra, Jacqueline L Chen, Andrea R Coravos, Ariel Dora Stern
Quantifying the use of connected digital products in clinical research. NPJ digital medicine 3 (2020)
Ariel Dora Stern, William J Gordon, Adam B Landman, Daniel B Kramer
Cybersecurity features of digital medical devices: an analysis of FDA product summaries. BMJ open 9 (6) (2019)

Ariel Dora Stern.css-eqlu8i{font-size:small;padding-left:4px;} (Ariel D Stern, Ariel Stern)

Publication Activity (10 Years)

Top Topics

Top Venues

Ariel Dora Stern (Ariel D Stern, Ariel Stern)